NCEL vs NERV

NewcelX Ltd. vs Minerva Neurosciences, Inc — Valuation Comparison 2026

NCEL

Pharmaceutical Preparations
NewcelX Ltd.
Quality
1.7
out of 10
Value Trap
12
SAFE
Price
$3.52
Last close
Models
7/13
Active
VS

NERV

Pharmaceutical Preparations
Minerva Neurosciences, Inc
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$4.91
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType NCEL Fair ValueNCEL Upside NERV Fair ValueNERV Upside
Bayesian DCF Intrinsic $0.86 -75.5% $1.70 -65.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $2.43 -30.9% $11.74 +139.1%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NCEL vs NERV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NCEL vs NERV — Which Stock Is More Undervalued?

NERV scores higher with a 3.4/10 quality rating vs NCEL's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NewcelX Ltd. (NCEL) and Minerva Neurosciences, Inc (NERV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NCEL currently trades at $3.52 with a QOC of 1.7/10, while NERV trades at $4.91 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).